Long-term safety and efficacy are observed after implantation of Zotarolimus-Eluting Stent in real-world clinical practice

2008 ◽  
Vol 4 (3) ◽  
pp. 338-344 ◽  
Author(s):  
Chi-Hang Lee ◽  
Adrian Low ◽  
Eric Hong ◽  
Bee-Choo Tai ◽  
Ing-Haan Lim ◽  
...  
Keyword(s):  
Clinical Practice ◽  
Real World ◽  
Safety And Efficacy

Long-term safety and efficacy of sirolimus-eluting stents versus bare-metal stents in real world clinical practice in Japan

2011 ◽  
Vol 26 (3) ◽  
pp. 234-245 ◽  
Author(s):  
Takeshi Kimura ◽  
Takeshi Morimoto ◽  
Yutaka Furukawa ◽  
Yoshihisa Nakagawa ◽  
Kazushige Kadota ◽  
...  
Keyword(s):  
Clinical Practice ◽  
Real World ◽  
Bare Metal Stents ◽  
Metal Stents ◽  
Bare Metal ◽  
Safety And Efficacy

scholarly journals Long-term safety of icatibant treatment of patients with angioedema in real-world clinical practice

Allergy ◽  
2017 ◽  
Vol 72 (6) ◽  
pp. 994-998 ◽  
Author(s):  
A. Zanichelli ◽  
M. Maurer ◽  
W. Aberer ◽  
T. Caballero ◽  
H. J. Longhurst ◽  
...  
Keyword(s):  
Clinical Practice ◽  
Real World

scholarly journals Effects of renal denervation on kidney function and long-term outcomes: 3-year follow-up from the Global SYMPLICITY Registry

2019 ◽  
Vol 40 (42) ◽  
pp. 3474-3482 ◽  
Author(s):  
Felix Mahfoud ◽  
Michael Böhm ◽  
Roland Schmieder ◽  
Krzysztof Narkiewicz ◽  
Sebastian Ewen ◽  
...  
Keyword(s):  
Renal Function ◽  
Real World ◽  
Active Sites ◽  
Renal Denervation ◽  
Uncontrolled Hypertension ◽  
Open Label ◽  
Hypertensive Patients ◽  
Safety And Efficacy

Abstract Aims Several studies and registries have demonstrated sustained reductions in blood pressure (BP) after renal denervation (RDN). The long-term safety and efficacy after RDN in real-world patients with uncontrolled hypertension, however, remains unknown. The objective of this study was to assess the long-term safety and efficacy of RDN, including its effects on renal function. Methods and results The Global SYMPLICITY Registry is a prospective, open-label registry conducted at 196 active sites worldwide in hypertensive patients receiving RDN treatment. Among 2237 patients enrolled and treated with the SYMPLICITY Flex catheter, 1742 were eligible for follow-up at 3 years. Baseline office and 24-h ambulatory systolic BP (SBP) were 166 ± 25 and 154 ± 18 mmHg, respectively. SBP reduction after RDN was sustained over 3 years, including decreases in both office (−16.5 ± 28.6 mmHg, P < 0.001) and 24-h ambulatory SBP (−8.0 ± 20.0 mmHg; P < 0.001). Twenty-one percent of patients had a baseline estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m2. Between baseline and 3 years, renal function declined by 7.1 mL/min/1.73 m2 in patients without chronic kidney disease (CKD; eGFR ≥60 mL/min/1.73 m2; baseline eGFR 87 ± 17 mL/min/1.73 m2) and by 3.7 mL/min/1.73 m2 in patients with CKD (eGFR <60 mL/min/1.73 m2; baseline eGFR 47 ± 11 mL/min/1.73 m2). No long-term safety concerns were observed following the RDN procedure. Conclusion Long-term data from the Global SYMPLICITY Registry representing the largest available cohort of hypertensive patients receiving RDN in a real-world clinical setting demonstrate both the safety and efficacy of the procedure with significant and sustained office and ambulatory BP reductions out to 3 years.

scholarly journals Long-term safety and efficacy of breast biopsy markers in clinical practice

2020 ◽  
pp. 1-7
Author(s):  
Sharon Smith ◽  
Clayton R. Taylor ◽  
Estella Kanevsky ◽  
Stephen P. Povoski ◽  
Jeffrey R. Hawley
Keyword(s):  
Clinical Practice ◽  
Breast Biopsy ◽  
Safety And Efficacy

Safety and efficacy analysis of long-term follow up real-world data with ibrutinib monotherapy in 58 patients with CLL treated in a single-center in Greece

2019 ◽  
Vol 60 (12) ◽  
pp. 2939-2945 ◽  
Author(s):  
Maria Dimou ◽  
Theodoros Iliakis ◽  
Vasileios Pardalis ◽  
Catherin Bitsani ◽  
Theodoros P. Vassilakopoulos ◽  
...  
Keyword(s):  
Real World ◽  
Single Center ◽  
Real World Data ◽  
Safety And Efficacy ◽  
World Data ◽  
Efficacy Analysis ◽  
Long Term Follow Up

scholarly journals How I manage ibrutinib intolerance and complications in patients with chronic lymphocytic leukemia

Blood ◽  
2019 ◽  
Vol 133 (12) ◽  
pp. 1298-1307 ◽  
Author(s):  
Deborah M. Stephens ◽  
John C. Byrd
Keyword(s):  
Clinical Trials ◽  
Clinical Practice ◽  
Chronic Lymphocytic Leukemia ◽  
Adverse Events ◽  
Real World ◽  
Lymphocytic Leukemia ◽  
Targeted Therapeutics ◽  
Therapeutic Approaches ◽  
Therapeutic Alternatives

Abstract Chronic lymphocytic leukemia (CLL) therapy has changed dramatically with the introduction of several targeted therapeutics. Ibrutinib was the first approved for use in 2014 and now is used for initial and salvage therapy of CLL patients. With its widespread use in clinical practice, ibrutinib’s common and uncommon adverse events reported less frequently in earlier clinical trials have been experienced more frequently in real-world practice. In particular, atrial fibrillation, bleeding, infections, and arthralgias have been reported. The management of ibrutinib’s adverse events often cannot be generalized but must be individualized to the patient and their long-term risk of additional complications. When ibrutinib was initially developed, there were limited therapeutic alternatives for CLL, which often resulted in treating through the adverse events. At the present time, there are several effective alternative agents available, so transition to an alternative CLL directed therapy may be considered. Given the continued expansion of ibrutinib across many therapeutic areas, investigation of the pathogenesis of adverse events with this agent and also clinical trials examining therapeutic approaches for complications arising during therapy are needed. Herein, we provide strategies we use in real-world CLL clinical practice to address common adverse events associated with ibrutinib.

Long-term safety and efficacy of nevirapine, stavudine and lamivudine in a real-world setting

AIDS ◽  
2001 ◽  
Vol 15 (6) ◽  
pp. 804-805 ◽  
Author(s):  
Peter Shalit ◽  
Pat Farrell ◽  
Pamela Lindgren
Keyword(s):  
Real World ◽  
Safety And Efficacy ◽  
Real World Setting
Sign in / Sign up

Export Citation Format

Share Document